Announcements Trials
Browse Landscape

Phase

Phase 1 21Phase 2 17Phase 1/2 4Phase 3 3Phase NA 1Phase 2/3 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Melanoma 8Neoplasms 3Skin Neoplasms 1Sarcoma 1Refractory Differentiated Thyroid Gland Carcinoma 1Neoplasm Metastasis 1Fever 1Differentiated Thyroid Cancer (DTC) 1

Interventions

Paclitaxel 20Gemcitabine 16Dexamethasone 16Bevacizumab 16Docetaxel 15Oxaliplatin 14Cyclophosphamide 13Carboplatin 12Capecitabine 12Sorafenib 11Fluorouracil 11Leucovorin 10Cisplatin 10pembrolizumab 9Pemetrexed 9Epoetin Alfa 9venetoclax 8Prednisone 8Fentanyl 8Drug Therapy 8Doxorubicin 8atezolizumab 7Rivaroxaban 7Rituximab 7Darbepoetin alfa 7Anastrozole 7Panitumumab 6Ondansetron 6Morphine 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms × trametinib × Clear all
NCT01682083 2026-04-21

COMBI-AD

Novartis

Phase 3 Completed
870 enrolled 15 charts 1 FDA
Dermatologic

Melanoma, Neoplasms

NCT01597908 2021-02-24

COMBI-v

Novartis

Phase 3 Completed
704 enrolled 13 charts
Dermatologic

Melanoma, Neoplasms

NCT01245062 2018-04-05

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

GlaxoSmithKline

Phase 3 Completed
322 enrolled 24 charts
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡